Cholecalciferol Supplementation Attenuates Bone Loss in Incident Kidney Transplant Recipients: A Prespecified Secondary Endpoint Analysis of a Randomized Controlled Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84).

Vitamin D deficiency, persistent hyperparathyroidism, and bone loss are common after kidney transplantation (KTx).

However, limited evidence exists regarding the effects of cholecalciferol supplementation on parathyroid hormone (PTH) and bone loss after KTx.

Who Took Part

According to the abstract, 193 patients were involved.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

In this prespecified secondary endpoint analysis of a randomized controlled trial, the researchers evaluated changes in PTH, bone metabolic markers, and bone mineral density (BMD).

Topics PubMed links to this paper include Bone Density, Cholecalciferol, Dietary Supplements, Kidney Transplantation, Osteoporosis, Parathyroid Hormone and Vitamin D.

The authors tagged it with the keywords BONE MINERAL DENSITY and CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84) in 193 patients.

The publication is from 2022 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Parathyroid Hormone (PTH 1-84) compound page, all human trials.